Affordable Care Act

Improve Affordable Care Act performance measurements 

Under the Affordable Care Act, the federal government requires hospitals to report patient outcomes and to identify and analyze costs for unnecessary treatments. Currently, due to the high mortality rate of sepsis and the lack of timely and sensitive diagnostics, hospitals aggressively treat patients with a variety of antifungal and antibiotic drugs. This overuse of drugs is driving high cost, antimicrobial resistance and patient morbidity. How hospitals identify and handle sepsis and sepsis-causing bloodstream infections may impact their performance measurements in the Hospital-Acquired Conditions (HAC) and the Hospital Readmissions Reduction Program. 

The T2Candida Panel can reduce costs and unnecessary treatments as well as help hospitals improve their performance measures by providing physicians with the diagnostic information they need to treat patients quickly and appropriately. 

The physician waiting room

Without T2MR technology and the T2Candida Panel, identifying the species associated with sepsis always requires a blood culture result followed by some type of post-blood culture speciation process. This process can take 2 to 6 days and can miss up to 50% of infections.1 It is common for physicians to initiate antimicrobial drugs empirically to patients while waiting for blood culture-based diagnostic results. 

The hope:  The right drug or drug combination is administered to only the patients that need it, therefore improving the patient outcome as well as reducing the length of stay and overall cost of treatment. 

The problem: In most cases the wrong drug or drug combination is administered – and for every one patient treated correctly, there are typically four who are not.

The need: Fast and accurate diagnostics so the right patients are quickly treated with the right drug. 

The wait is over

Powered by T2MR, the T2Candida Panel provides species-specific results direct from whole blood with no blood culture in an average of 4.3 hours compared to the 2 to 6 days required for blood culture-based diagnostics. With a sensitivity of 91.1% versus the reported 50% sensitivity of blood culture based diagnostics, T2Candida Panel provides physicians with the ability to administer specific, effective antimicrobials quickly and confidently.2,1 The appropriate use of targeted antimicrobials can reduce patients’ length of stay, lower mortality and reduce the threat of resistant organisms. 

Additionally, a rapid negative test result from the T2Candida Panel may enable physicians to avoid or discontinue unnecessary antifungal treatment, saving money, reducing toxicity to the patient and lowering the risk of antimicrobial resistance in the hospital. 

Healthcare reform initiatives are designed to improve the efficiency and effectiveness of care, thereby reducing overall healthcare expenditures. The T2Candida Panel, without any need for blood culture, can lower healthcare costs, improve outcomes and lower mortality rates.

1. Pappas, P. G., Kauffman, C. A., Andes, D. R., et. al. (2015). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical infectious diseases, civ933.
2 .Mylonakis, E., Clancy, C.J., Ostrosky-Zeichner, et. al. (2015). T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical TrialClinical infectious diseases, ciu959.